Showing 5801-5810 of 8793 results for "".
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug App
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459833/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459834/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Delicious Living magazine recognizes Wildly Natural Seaweed Body Creamhttps://practicaldermatology.com/news/20120229-delicious_living_magazine_recognizes_wildly_natural_seaweed_body_cream/2459862/The Delicious Living 2012 Beauty & Body Award for “Best New Product” went to The Seaweed Bath Co.'s Wildly Natural SeaweedTM Body Cream, the company announced. Delicious Living chose winners based on the products' efficacy without sacrificing purity, innovation and their dedication to raising standa
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Zasocitinib Phase 3 Data Suggests Potential for Once-Daily Psoriasis Pillhttps://practicaldermatology.com/news/zasocitinib-phase-3-data-sugges-potential-for-once-daily-psoriasis-pill/2484981/Oral TYK2 inhibitor zasocitinib (TAK-279) met all primary and 44 ranked secondary endpoints in two pivotal Phase 3 trials for moderate-to-severe plaque psoriasis, according to a December 18 press release from Takeda. Results f
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://practicaldermatology.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- First Patient Enrolled in Nemolizumab Study for Chronic Itch Without Causehttps://practicaldermatology.com/news/first-patient-enrolled-in-nemolizumab-study-for-chronic-itch-without-cause/2484883/Galderma announced the enrollment first patient in a phase II clinical trial investigating nemolizumab for the treatment of Chronic Pruritus of Unknown Origin (CPUO), according to a press release from the manufacturer. The tr